TY  - GEN
AU  - Bendell,Johanna C
AU  - Varghese,Anna M
AU  - Hyman,David M
AU  - Bauer,Todd M
AU  - Pant,Shubham
AU  - Callies,Sophie
AU  - Lin,Ji
AU  - Martinez,Ricardo
AU  - Wickremsinhe,Enaksha
AU  - Fink,Aaron
AU  - Wacheck,Volker
AU  - Moore,Kathleen N
TI  - A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
SN  - 1557-3265
PY  - 2019///1220
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Biomarkers
KW  - Combined Modality Therapy
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - diagnosis
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Protein Kinase Inhibitors
KW  - Pyridines
KW  - Quinolones
KW  - Retreatment
KW  - TOR Serine-Threonine Kinases
KW  - antagonists & inhibitors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-17-3421
ER  -